Denali Therapeutics Announces Proposed Offering of Common Stock
19 October 2022 - 7:40AM
Denali Therapeutics Inc. (NASDAQ: DNLI) today announced that it
intends to offer and sell $250 million of shares of its common
stock in an underwritten public offering. In addition, Denali
Therapeutics intends to grant the underwriters a 30-day option to
purchase up to an additional fifteen percent (15%) of the shares of
common stock offered. The proposed offering is subject to market
and other conditions, and there can be no assurance as to whether
or when the offering may be completed, or as to the actual size or
terms of the offering.
Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and
Jefferies LLC are acting as joint book-running managers for the
offering. Berenberg Capital Markets LLC, Cantor Fitzgerald &
Co. and H.C. Wainwright & Co., LLC are acting as co-managers
for the offering.
The shares will be offered by Denali Therapeutics pursuant to a
Registration Statement on Form S-3, which was automatically
effective upon filing with the SEC on February 28, 2022, and Denali
Therapeutics will file a preliminary prospectus supplement to which
this communication relates, copies of which can be accessed for
free through the SEC’s website at www.sec.gov. The final terms of
the offering will be disclosed in a final prospectus supplement to
be filed with the SEC.
When available, a copy of the preliminary
prospectus supplement, the final prospectus supplement and the
accompanying prospectus relating to this offering may also be
obtained from:
Goldman Sachs & Co. LLC, Attention:
Prospectus Department, 200 West Street, New York, NY 10282,
telephone: 1-866-471-2526, fax: 212-902-9316, email:
prospectus-ny@ny.email.gs.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-866-803-9204 or by email:
prospectus-eq_fi@jpmchase.com; or Jefferies LLC, Attention: Equity
Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New
York, NY 10022, by telephone at (877) 821-7388, or by email at
prospectus_department@jefferies.com.
This press release does not constitute an offer
to sell or a solicitation of an offer to buy, nor will there be any
sale of these securities in any state or other jurisdiction in
which such offer, solicitation, or sale would be unlawful before
registration or qualification under the securities laws of that
state or jurisdiction.
About Denali Therapeutics
Denali Therapeutics is a biopharmaceutical
company developing a broad portfolio of product candidates
engineered to cross the blood-brain barrier (BBB) for
neurodegenerative diseases. Denali Therapeutics pursues new
treatments by rigorously assessing genetically validated targets,
engineering delivery across the BBB and guiding development through
biomarkers that demonstrate target and pathway engagement. Denali
Therapeutics is based in South San Francisco.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the federal securities laws. These
statements involve risks and uncertainties that could cause actual
results to differ materially, including, but not limited to,
whether or not Denali Therapeutics will be able to raise capital
through the sale of shares of common stock or consummate the
offering, the final terms of the offering, the satisfaction of
customary closing conditions, prevailing market conditions, the
anticipated use of the proceeds of the offering which could change
as a result of market conditions or for other reasons, and the
impact of general economic, industry or political conditions in the
United States or internationally. Additional risks and
uncertainties relating to the offering, Denali Therapeutics and its
business can be found under the heading “Risk Factors” in Denali
Therapeutics’ most recent current, quarterly and annual reports
filed with the SEC and in the preliminary prospectus supplement and
accompanying prospectus relating to the offering to be filed with
the SEC. Denali Therapeutics assumes no duty or obligation to
update or revise any forward-looking statements for any reason.
Investor Relations Contact:
Laura Hansen, Ph.D.Vice President, Investor Relations(650)
452-2747hansen@dnli.com
Media Contact:
dna CommunicationsAngela Salerno-RobinSenior Vice President,
Media Relations, Healthcare+ 1 212 445
8219Asalerno-robin@dna-comms.com
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Denali Therapeutics (NASDAQ:DNLI)
Historical Stock Chart
From Jul 2023 to Jul 2024